Tesamorelin for reducing liver fat in fatty liver disease
Part of Digestive system clinical trials.
This trial tests if tesamorelin, a daily injection, can reduce liver fat in adults with fatty liver disease. It may help people whose liver has fat but is not yet scarred into cirrhosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a fatty liver confirmed by a special MRI scan showing at least 10% fat.
- Your liver is not scarred (no cirrhosis) based on a stiffness test or other evidence.
- Your weight has been stable (within 5%) for the past 3 months.
- You can give yourself daily shots under the skin (or have someone who can help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This trial tests new medicines for adults with fatty liver disease (MASLD) that has already caused some liver scarring. It aims to see if these drugs can help prevent the liver disease from getting worse.
This trial tests a supplement called TOTUM-448 to see if it can reduce liver fat and improve heart health in people with a fatty liver condition (MASLD). If you have excess liver fat and are overweight, this study could help find new ways to manage your condition.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This study tests whether adding a liver stiffness measurement to a lifestyle program helps people with MASLD (a type of fatty liver disease) improve their liver health. It is designed for people who have fatty liver and at least one sign of metabolic syndrome, like high blood pressure or diabetes.
This trial tests a new medication called ACT500 for people with fatty liver disease (MASLD). The goal is to see if it is safe and how the body processes it. You may be able to join if you have at least 10% liver fat, some liver scarring or damage, and certain metabolic risk factors like being overweight or having prediabetes.
Hear when a new Metabolic Associated Steatotic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.